Triple Anti-Angiogenic Therapy for Brain Tumors

脑肿瘤的三重抗血管生成疗法

• 批准号: 6952023
• 负责人: W K ALFRED Yung
• 金额: $ 25.1万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-03-01 至 2008-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6952023
• 关键词: Adenoviridae; angiogenesis inhibitors; angiopoietins; antisense nucleic acid; astrocytoma; athymic mouse; biological signal transduction; biotechnology; cell line; clinical research; combination cancer therapy; cycloheximide; gene expression; gene therapy; genetic regulation; molecular oncology; neoplasm /cancer blood supply; neoplasm /cancer therapy; nonhuman therapy evaluation; protein protein interaction; transcription factor; transfection /expression vector; vascular endothelial growth factors; virus replication

DESCRIPTION (provided by applicant): Angiogenesis is critical for the development and maintenance of glioblastomas, the most malignant and most common form of primary brain tumors. Current evidence indicates that recruitment of tumor vessels from normal surrounding tissue, and development and maintenance of tumor angiogenesis require a delicate balance between the timing and level of expression of two major angiogenesis factors: Angiopoietin-2 (Ang-2) and the vascular endothelial growth factor-A (VEGF-A). The combination of Ang-2 and VEGF-A expressions results in loosening of peri-endothelial support rendering the newly exposed endothelial cells able to multiply. We hypothesize that there is a regulatory signaling loop involving the coordinated and sequential expression of VEGF and Ang-2, and that elucidating the underlying mechanisms can lead to developing a better model for the angiogenic process that occurs in human gliomas. Importantly, we have uncovered the expression of Tie2 in glioma cells. Moreover, exploiting the interdependence between VEGFand Ang-2 could be used to develop more effective and rational anti-angiogenesis therapies for brain tumors than currently exist. Therefore, in this application we shall aim to uncover the mechanisms of interaction between Ang-2 and VEGF-A, the role of Ang-2 expression in a dynamic tumor model of glioma angiogenesis, and to develop an effective treatment based on the simultaneous targeting of Ang-2, using conditionally-replicative adenoviruses, and direct down modulation of VEGF using antisense strategies. The specific aims are as follows: Specific Aim 1: To characterize the modulation of VEGF-A by Ang-2; Specific Aim 2: To determine the effects of Angiopoietin-2 on the growth kinetics and angiogenesis development in a glioma model; and Specific Aim 3: To examine the anti-glioma effect of combined therapies based on the transfer of Angiopoietin-2, using oncolytic adenoviruses, and anti-sense VEGF. This project should yield important mechanistic information about the abnormal regulation of angiogenesis in gliomas. Furthermore, data obtained from our studies will hopefully constitute a rational basis for the development of a Phase 1/11clinical trial to test the toxicity and efficacy of a triple treatment for malignant gliomas, which combines the overexpression of Ang-2, decreased VEGF expression, and oncolysis.

描述（由申请人提供）：血管生成对于胶质母细胞瘤的发展和维持至关重要，胶质母细胞瘤是最恶性和最常见的原发性脑肿瘤。目前的证据表明，从正常周围组织募集肿瘤血管以及肿瘤血管生成的发展和维持需要两种主要血管生成因子的表达时间和水平之间的微妙平衡：血管生成素-2 (Ang-2) 和血管内皮生长A 因子（VEGF-A）。 Ang-2 和 VEGF-A 表达的结合导致内皮周围支持的松动，使新暴露的内皮细胞能够增殖。我们假设存在一个涉及 VEGF 和 Ang-2 协调和顺序表达的调节信号环路，并且阐明潜在机制可以为人类神经胶质瘤中发生的血管生成过程开发更好的模型。重要的是，我们发现了 Tie2 在神经胶质瘤细胞中的表达。此外，利用 VEGF 和 Ang-2 之间的相互依赖性可用于开发比目前更有效、更合理的脑肿瘤抗血管生成疗法。因此，在本申请中，我们的目标是揭示Ang-2和VEGF-A之间的相互作用机制，Ang-2表达在胶质瘤血管生成的动态肿瘤模型中的作用，并开发基于同时靶向的有效治疗方法Ang-2，使用条件复制腺病毒，并使用反义策略直接下调 VEGF。具体目标如下： 具体目标1：表征Ang-2对VEGF-A的调节作用；具体目标 2：确定 Angiopoietin-2 对神经胶质瘤模型生长动力学和血管生成发育的影响；具体目标 3：检查基于血管生成素-2 转移、溶瘤腺病毒和反义 VEGF 的联合疗法的抗神经胶质瘤效果。该项目应该会产生有关神经胶质瘤血管生成异常调节的重要机制信息。此外，从我们的研究中获得的数据有望为 1/11 期临床试验的开发奠定合理的基础，以测试恶性胶质瘤三联治疗的毒性和疗效，该三联治疗结合了 Ang-2 的过度表达、VEGF 表达的减少、和溶瘤作用。